-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100

Benzinga·07/29/2026 13:40:10
Listen to the news
Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $100.